Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDE892 + RG6505
- Development stage
- Unknown
- Lead developer
- IDEAYA Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
IDE892 + RG6505 is an investigational combination regimen consisting of IDE892, an orally bioavailable, methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5), and RG6505, a pan-RAS inhibitor. Developed through a clinical collaboration between IDEAYA Biosciences and Roche, this combination is designed to exploit synthetic lethality in cancers with co-occurring genetic alterations. Specifically, MTAP deletion leads to a buildup of MTA, which cooperates with IDE892 to selectively inhibit PRMT5, while RG6505 blocks all forms of mutated RAS proteins that drive tumor growth. The combination is being evaluated in Phase 1 clinical trials for the treatment of MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma (PDAC).
- Other names
- IDE892 + RG6505IDE892 plus RG6505IDE-892 plus RG6505IDE 892 plus RG6505
02
Targets
PRMT5 (Protein arginine N-methyltransferase 5)HRAS (H-Ras protein)
Beyond the preview
Go deeper on IDE892 + RG6505.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDE892 + RG6505.